10-Q: Grace Therapeutics Reports Positive Phase 3 Trial Results for GTx-104 and Provides Financial Update

Grace Therapeutics announces positive Phase 3 results for GTx-104 and provides an update on its financial condition for the quarter ended December 31, 2024.

Summary

• Grace Therapeutics is focused on developing and commercializing products for rare and orphan diseases.
• The company's lead drug candidate, GTx-104, met its primary endpoint in a Phase 3 trial, showing a reduction in clinically significant hypotension compared to oral nimodipine.
• The company plans to submit an NDA to the FDA for GTx-104 in the first half of calendar year 2025.
• The company completed a private placement in February 2025, raising approximately $13.8 million in net proceeds.
• For the three months ended December 31, 2024, the company reported a net loss of $4.2 million, or $0.36 per share.
• For the nine months ended December 31, 2024, the company reported a net loss of $10.2 million, or $0.89 per share.
• As of December 31, 2024, cash and cash equivalents were $11.1 million.
• The company believes its existing cash and cash equivalents will be sufficient to sustain planned operations through at least 12 months from the issuance date of the financial statements.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. The positive Phase 3 trial results for GTx-104 are encouraging, and the recent capital raise provides financial stability. However, the company's history of operating losses and the need for future funding introduce uncertainty.

Positives

• GTx-104 demonstrated positive Phase 3 results, potentially addressing significant challenges with oral nimodipine administration.
• The company has a clear plan to submit an NDA to the FDA for GTx-104 in the first half of calendar year 2025.
• The recent private placement provides additional funding to support the company's operations.
• The company believes its existing cash and cash equivalents will be sufficient to sustain planned operations through at least 12 months from the issuance date of the financial statements.
• The company's therapeutic pipeline consists of three unique clinical-stage drug candidates supported by an intellectual property portfolio of more than 40 granted and pending patents in various jurisdictions worldwide.

Negatives

• The company has incurred operating losses and negative cash flows from operations in each period since its inception.
• The company expects to incur significant expenses and continued operating losses for the foreseeable future.
• The company will require additional capital to fund its daily operating needs beyond the next 12 months.
• The company does not expect to generate revenue from product sales unless and until it successfully completes drug development and obtains regulatory approval, which is subject to significant uncertainty.

Risks

• The company is heavily dependent on the success of its lead drug candidate, GTx-104.
• Clinical development is a lengthy and expensive process with an uncertain outcome.
• The company is subject to uncertainty relating to healthcare reform measures and reimbursement policies.
• The company may be unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell its drug products.
• The company's success depends in part upon its ability to protect its intellectual property for its drug candidates.
• The company does not have internal manufacturing capabilities and depends on third-party manufacturers.
• The company may encounter difficulties involving production yields, regulatory compliance, quality control and quality assurance, as well as shortages of qualified personnel.

Future Outlook

The company plans to submit an NDA to the FDA for GTx-104 in the first half of calendar year 2025 and believes its existing cash and cash equivalents will be sufficient to sustain planned operations through at least 12 months from the issuance date of the financial statements. The company will require additional capital to fund its daily operating needs beyond that time.

Management Comments

• We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies.

Industry Context

The company operates in the biopharmaceutical industry, focusing on rare and orphan diseases. This is an attractive area for drug development due to the potential for orphan drug designation and exclusivity from the FDA. The company's strategy involves reformulating existing pharmaceutical compounds to achieve improvements over the current standard of care.

Comparison to Industry Standards

• Nimodipine is the only approved drug that has been clinically shown to improve neurological outcomes in aSAH patients.
• NYMALIZE, manufactured and sold by Azurity Pharmaceuticals, is a branded oral liquid solution of nimodipine.
• NIMOTOP is an injectable form of nimodipine manufactured by Bayer Healthcare, approved in the European Union, China, and other regulated markets (but not in the United States).
• The company estimates that the total addressable market for aSAH is approximately $300 million in the U.S.
• The company commissioned an independent market research survey of hospital administrators, critical and neuro intensive care physicians at institutions with Comprehensive or Advanced Stroke Center certification who are involved in purchasing decisions for their institutions/units, respondents reported 80% likelihood of adopting an IV formulation of nimodipine (GTx-104), assuming 100% bioavailability, better safety, no food effects, effective hypotension management, potential hospital value and patient value.

Legal Proceedings

• In the ordinary course of business, the Company is at times subject to various legal proceedings and disputes.
• The Company assesses its liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available.
• Where it is probable that the Company will incur a loss and the amount of the loss can be reasonably estimated, the Company records a liability in its unaudited condensed consolidated financial statements.
• These legal contingencies may be adjusted to reflect any relevant developments on a quarterly basis.
• Where a loss is not probable or the amount of loss is not estimable, the Company does not accrue legal contingencies.
• While the outcome of legal proceedings is inherently uncertain, based on information currently available, management believes that it has established appropriate legal reserves.
• No reserves or liabilities have been accrued at December 31, 2024.

Related Party Transactions

• The 2023 Private Placement included the issuance of Common Shares, 2023 Pre-funded Warrants, and 2023 Common Warrants to related parties Shore Pharma LLC, an entity that was controlled by Vimal Kavuru, the Chair of the Companys Board of Directors, at the time of the 2023 Private Placement, and SS Pharma LLC, the beneficial owner of 5.5% of Common Shares outstanding prior to the 2023 Private Placement, resulting in proceeds of $2,500.
• As of December 31, 2024 and March 31, 2024, the balance of derivative warrant liabilities from these related parties was $1,265 and $1,453, respectively.

Stakeholder Impact

• Positive Phase 3 results for GTx-104 could improve treatment options for aSAH patients.
• The company's financial condition impacts its ability to continue operations and develop new therapies.
• The company's success depends on its ability to protect its intellectual property and maintain relationships with third-party manufacturers.
• The company's performance is subject to various risks and uncertainties, including regulatory approvals and market conditions.

Next Steps

• Submit an NDA to the FDA for GTx-104 in the first half of calendar year 2025.
• Continue clinical trial expenses to further the Phase 3 clinical trial for GTx-104.
• Continue pre-commercial planning, commercial team buildout, and product launch if GTx-104 is approved.
• Raise additional capital in order to maintain adequate liquidity.

Key Dates

Keywords

GTx-104, nimodipine, aSAH, clinical trial, FDA, NDA, private placement, financial results, Grace Therapeutics, pharmaceutical, rare diseases, orphan diseases